PD-1/PD-L1-targeted monoclonal antibodies (mAbs) are now the standard of care for 16 different types of cancer and tissue-agnostic indication. Since our first PD-1/PD-L1 trial landscape survey conducted in September 2017 (Ann. Oncol. 24, 84–89; 2019), 23 additional approvals have been granted to PD-1/PD-L1 mAbs by the FDA, and 4 new PD-1 mAbs have reached the market, bringing the total on the global market to 9. These achievements were powered by some of the largest clinical trial programmes ever in oncology. This report analyses the current landscape of clinical trials evaluating mAbs against PD-1/PD-L1.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD